This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ahrendt, S. A. Articles by Sidransky, D. Search for Related Content PubMed PubMed Citation Articles by Ahrendt, S. A. Articles by Sidransky, D.

Alcohol Consumption and Cigarette Smoking Increase the Frequency of p53 Mutations in Non-Small Cell Lung Cancer¹

Departments of Surgery [S. A. A.] and Biostatistics [M-J. A.], Medical College of Wisconsin, Milwaukee, Wisconsin 53226, and Departments of Otolaryngology-Head and Neck Surgery [J. T. C., L. W., J. J., D. S.] and Surgery [S. C. Y.], The Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland 21287

	ABSTRACT

Top ABSTRACT Introduction Patients and Methods Results Discussion REFERENCES

 
Epidemiological studies have demonstrated a strong association between tobacco use and lung cancer; however, the genetic targets of these carcinogens and the role of other environmental agents in this process have yet to be defined. We examined the contribution of alcohol use and cigarette smoking to p53 gene mutations in patients with non-small cell lung cancer. Mutations of the p53 gene were detected by sequence analysis in 105 patients with non-small cell lung cancer. Patient characteristics significantly associated with p53 gene mutations were determined using logistic regression. Mutations in the p53 gene were present in 53% of the patients (56 of 105). p53 mutations were more common in patients who used alcohol than in patients who consumed less than one drink per day (72 versus 39%; P = 0.003), and were detected more often smokers than nonsmokers (58% versus 10%, P = 0.02). Mutations in the p53 gene were present more often (P = 0.01) in alcohol drinkers who smoked cigarettes [76% (31 of 41)], than in nondrinkers (<1 drink per day) who smoked cigarettes [42% (20 of 48)] or in nondrinkers who did not smoke [14% (1 of 7)]. In conclusion, alcohol consumption and tobacco use are both associated with p53 mutations in non-small cell lung cancer. The link between exposure to both alcohol and tobacco and p53 mutations raises the possibility that alcohol may enhance the mutagenic effects of cigarette smoke in the lung.

	Introduction

Top ABSTRACT Introduction Patients and Methods Results Discussion REFERENCES

 
Lung cancer is the leading cause of cancer deaths among males and females in the United States (1) . Epidemiological evidence suggests that most cases of lung cancer are directly attributable to cigarette smoking (2) . Only 5–10% of all of the lung cancer cases occur in patients without a prior history of cigarette smoking (3) . Compared with nonsmokers, smokers have a 10-fold greater risk of dying from lung cancer, and in heavy smokers this risk increases to 15- to 25-fold (2) . In contrast, the relationship between alcohol consumption and lung cancer is less well defined. Alcohol consumption is closely related to cigarette smoking, which makes it difficult to assess the independent risk of alcohol on lung cancer alone (4) . Furthermore, minor alleles in the D2 dopamine receptor gene, previously implicated in chronic alcoholism, have recently been reported to play a role in determining nicotine addiction (5) . Several recent studies have controlled for tobacco use and have demonstrated an increased incidence of lung cancer in heavy alcohol drinkers, with one study (4) reporting an adjusted odds ratio of 1.8 for alcohol drinkers (one or more drinks of alcohol per day) compared with infrequent drinkers (4 , 6, 7, 8) .

Molecular epidemiological studies have begun to link specific environmental carcinogens with mutational events in cancer progression (9 , 10) . The p53 gene has been a common target of these mutational studies because it is the most frequently mutated gene in human cancer (10) . These studies have also shown that the p53 mutational spectrum of smoking-related neoplasms is distinctly different from that present in non-smoking-related cancers. Recently, benzo(a)pyrene diol epoxide, the active form of benzopyrene and a potent carcinogen in cigarette smoke, has been shown to bind preferentially to select regions of the p53 gene (11 , 12) . Formation of these benzopyrene adducts likely reflects the high frequency of certain p53 mutations in smoking-associated tumors and correlates with several known mutational hotspots in the p53 gene (12) . In addition, exposure to other environmental agents such as ethanol may further augment the mutational effect of tobacco smoke (13) . In head and neck squamous cell cancer, a cancer long-associated with both tobacco and alcohol use in epidemiological studies, the frequency of p53 mutations and overexpression is significantly higher in patients who smoked cigarettes and drank alcohol than in patients who only smoked cigarettes (13 , 14) . Although heavy alcohol consumption increases lung cancer risk, the effect of cigarette smoking and ethanol intake on the frequency of p53 gene mutations in lung cancer is not known. In the present study, we studied the effect of alcohol consumption and cigarette smoking on mutation of the p53 tumor suppressor gene in patients with non-small cell lung cancer.

	Patients and Methods

Top ABSTRACT Introduction Patients and Methods Results Discussion REFERENCES

 
Patients.
One hundred forty-five consecutive patients undergoing surgical resection of non-small cell lung cancer at The Johns Hopkins Hospital or the Johns Hopkins Bayview Medical Center were entered into a prospective study examining the prognostic significance of p53 mutations in non-small cell lung cancer. For the present analysis, which examined the effect of alcohol consumption and smoking on p53 mutations, we elected to continue accruing patients until at least 10 nonsmokers with lung cancer had been identified. Five patients were excluded because a smoking history could not be obtained (three patients) or they had received preoperative chemotherapy (two patients). Of the remaining 140 patients, 130 (93%) had a history of cigarette smoking.

Demographic data were collected from patient interviews and a review of the hospital charts and from The Johns Hopkins Hospital Tumor Registry. Pathological stage was determined using the revised International System for Staging Lung Cancer (15) . Tumors from patients with squamous cell carcinoma or adenocarcinoma of the lung and a history of a second primary squamous cell or adenocarcinoma at a different site underwent careful pathological review of both cancers to exclude a pulmonary metastasis from a nonlung primary tumor. Four patients, in whom the possibility of metastases could not be excluded, were not included in the study. Demographic data were compiled by staff members who had no knowledge of the mutational analysis of the p53 gene in the patient’s tumor. This research protocol was approved by the Joint Committee on Clinical Investigation of The Johns Hopkins School of Medicine, and informed consent was obtained from all of the patients.

The history of alcohol consumption and cigarette smoking was obtained from patient interview and clinic notes or from the tumor registry. Patients were classified as alcohol drinkers if they consumed one or more drinks (one drink being defined as 1 ounce of 86-proof hard liquor, one 3.6-ounce glass of wine containing 12% alcohol, or one 12-ounce can of beer) per day on average during the 20 years before being diagnosed with lung cancer, as occasional drinkers if they consumed alcohol but less than one drink per day on average, and as nondrinkers if they consumed less than one drink per day or abstained from alcohol (13) . Nonsmokers were defined as patients who had smoked <100 cigarettes in their lifetime (4) . All of the smokers had at least a 10-pack-year history of smoking. Lifetime cigarette consumption was quantitated by averaging the number of packs smoked over the number of total smoking years (pack-years). Smoking patients were also stratified by the number of years they had quit smoking in 5-year intervals before the diagnosis of lung cancer or whether they were still smoking cigarettes.

Molecular Analysis.
Portions of the patient’s primary lung cancer were collected and promptly frozen at -80°C. Sections of the primary tumor were stained with H&E and examined by light microscopy. Tumors with low neoplastic cellularity (<70%) were further microdissected to remove contaminating normal cells, and DNA was isolated. A 1.8-kb fragment of the p53 gene (exons 5 through 9) was amplified from the primary tumor from the first 95 patients with a history of cigarette smoking and in all of the 10 nonsmokers. Exons 5 through 9 of the p53 gene were sequenced directly using cycle sequencing (16) . In addition, the same DNA isolated from all of the 105 tumors was further sequenced (exons 2 through 11) using the GeneChip p53 assay (Affymetrix Inc., Santa Clara, CA) as described previously (17) . Discrepancies between these two techniques (exons 5 through 9) were resolved by a third assay (oligonucleotide-specific hybridization) as described previously (17) .

Statistical Methods.
Clinical and pathological characteristics between smokers and nonsmokers were compared using ² or Fisher’s exact test for categorical variables and Wilcoxon’s nonparametric rank test for continuous variables. The association between multiple clinical and pathological variables and mutation of the p53 gene were examined by logistic regression. Statistical analysis was performed using SAS system software.

	Results

Top ABSTRACT Introduction Patients and Methods Results Discussion REFERENCES

 
Patient Characteristics.
One hundred and five patients with non-small cell lung cancer undergoing surgical resection were finally included in this study. This group included the 10 nonsmokers and 95 smokers whose tumors had previously undergone p53 sequence analysis. A history of alcohol intake was available from 97 (92%) of the 105 patients. Forty-four % of these patients had an alcohol intake of one or more drinks per day. Twenty-one % of the patients drank alcohol occasionally (less than one drink per day), and 35% abstained from alcohol. No significant differences in age, gender, tumor cell type, tumor stage, tumor size, or tumor grade were observed among patients who drank more than one drink per day and those who drank less than one drink per day.

Clinical characteristics for smokers (n = 95) and nonsmokers (n = 10) with non-small cell lung cancer are shown in Table 1 . Nonsmokers who developed non-small cell lung were significantly older, more often female, and more likely to develop adenocarcinoma and had smaller cancers than smokers. Nonsmokers with primary lung cancer were also more likely to have a prior history of cancer [pancreas, breast, colon, lymphoma, prostate, melanoma (excludes nonmelanoma skin cancer)] than patients with a history of cigarette smoking (60 versus 24%; P = 0.02). A trend toward earlier stage cancers was also observed in the nonsmokers.

View this table: [in this window] [in a new window]   Table 2 Characteristics of alcohol drinkers ( one drink/day) and nondrinkers (<one drink/day) with non-small cell lung cancer

Molecular Analysis.
p53 sequence analysis was performed on tumor samples from 105 patients with non-small cell lung cancer using direct sequencing and the p53 GeneChip. At least one mutation of the p53 gene was identified in 56 (53%) of 105 tumors. A comparison between these two sequencing techniques has been reported previously (17) . One tumor contained two p53 mutations for a total of 57 mutations in 105 non-small cell lung cancers (Table 3) . The most common p53 mutations were GCTA transversions and GCAT transitions. Only one p53 mutation was present among the 10 nonsmokers, which precluded any comparison of mutation spectra among nonsmokers and smokers. GCAT transitions were more common in alcohol drinkers [6 (14%) of 43] than in nondrinkers [2 (4%) of 54]; however, this difference failed to reach statistical significance (P = 0.12). No other statistically significant differences were observed among the mutation spectrum from nondrinkers and the mutation spectrum from patients consuming at least one drink per day (data not shown). Thirty-four % of the p53 mutations included frame-shifts, deletions, splice sites, or termination codons. These mutations would be predicted to encode truncated p53 proteins that immunohistochemical analysis usually fails to detect.

Alcohol use, smoking history, and cell type were then examined in a logistic regression model to define independent variables associated with mutation of the p53 gene in non-small cell lung cancer. A history of alcohol intake (1 drink per day) was the variable with the strongest statistical association with p53 mutations (odds ratio, 3.9; 95% confidence interval, 1.5–10; P < 0.005). Cell type was also significantly associated with p53 mutations with squamous cell cancers having a greater frequency of mutations than adenocarcinomas (odds ratio, 2.9; 95% confidence interval, 1.2–7.2; P < 0.02). In the multivariate analysis, smoking was associated with the greatest overall risk (odds ratio, 6.5) of harboring a p53 mutation in non-small cell lung cancer. However, smoking was also associated with a large confidence interval, in large part attributable to the low frequency of nonsmokers in the population and the low incidence of p53 mutations and squamous cell histology in this group of patients (95% confidence interval, 0.73–58; P = 0.09). Therefore, we further examined the role of smoking in mutations of the p53 gene in patients with only adenocarcinoma of the lung (9 of 10 nonsmokers developed adenocarcinoma). Mutations of the p53 gene were present in 46% of smokers with adenocarcinoma (21 of 46) but in none of the 9 nonsmokers with adenocarcinoma of the lung (P = 0.016).

We also examined the quantitative effect of alcohol consumption and cigarette consumption (in pack-years) on the p53 mutation rate. Smoking intensity was weakly correlated with alcohol intake. The median number of pack-years smoked (50 pack-years) among the alcohol drinkers (1 drink per day) was not significantly greater (Pearson correlation coefficient, 0.10; P < 0.39) than the median number of pack-years smoked (40 pack-years) among the nondrinkers (1 drink per day). The frequency of p53 mutations was significantly greater in alcohol drinkers than in nonsmokers and nondrinkers, and this increase was present in both light (<50 pack-years) and heavy (50 pack-years) smokers (Table 5) . There was also a trend toward an increased frequency of p53 mutations in light smokers (<50 pack-years) who consumed alcohol when compared with light smokers who consumed less than one drink per day (82 versus 53%; P = 0.07).

View larger version (15K): [in this window] [in a new window]   Fig. 1. Influence of tobacco and alcohol use on the odds ratio for p53 mutations in patients with non-small cell lung cancer. The odds ratio for tobacco use but no alcohol use (<1 drink per day) versus no tobacco or alcohol use was 4.3 (95% confidence interval, 0.8–38.4; P = 0.19), for tobacco and alcohol use (1 drink per day) versus no tobacco or alcohol use was 18.6 (95% confidence interval, 2.0–174; P = 0.01), and for tobacco and alcohol use versus tobacco use but no alcohol use was 4.3 (95% confidence interval, 1.7–10.8; P < 0.01). *, P 0.01 versus tobacco and alcohol use.

	Discussion

Top ABSTRACT Introduction Patients and Methods Results Discussion REFERENCES

Alcohol consumption is an independent risk factor for cancers of the esophagus, pharynx, larynx, and liver (18) . A strong synergism between alcohol and smoking exists for cancers of the head and neck (18) . Ethanol is not itself genotoxic, and neither it nor alcoholic beverages are tumorigenic in animal models (18) . However, both tobacco and alcohol use are independently associated with p53 mutations in head and neck squamous cell cancers (13) . Several mechanisms have been postulated to explain how alcohol may potentiate the effect of environmental carcinogens. In animal studies, alcohol has been demonstrated to suppress hepatic clearance of low molecular weight nitrosoamines present in cigarette smoke by inhibiting several isoforms of the cytochrome P450 superfamily (18) . This inhibition then leads to an increase in the dose-delivery of nitrosoamines to posthepatic tissues and an increase in the formation of DNA adducts (18) . Furthermore, acetaldehyde, the initial breakdown product of ethanol inhibits the DNA repair enzyme O⁶-methylguanine DNA methyltransferase (19) . If left unrepaired by O⁶-methylguanine DNA methyltransferase, O⁶-methylguanine may pair with thymine during DNA replication. In the present study, a nonsignificant trend toward an increase in GCAT transitions was observed among alcohol drinkers. The present study demonstrates that alcohol may also play an important role in the pathogenesis of lung cancer.

Prior studies that examined the effect of cigarette smoking on mutations of the p53 gene in various cancer types have yielded conflicting results (20, 21, 22, 23, 24, 25, 26, 27, 28, 29) . Several studies have used immunohistochemical analysis to evaluate the p53 protein; this method has substantial false-negative and false-positive rates when compared with direct gene sequencing (21, 22, 23) . In the present study, 34% of the 57 mutations would have resulted in a truncated p53 protein, which usually do not stain with labeled anti-p53 antibodies. Several reports have correlated the frequency of p53 mutations with lifetime tobacco exposure and have not included or have included very few nonsmokers to achieve a statistically meaningful result (24, 25, 26) . Other investigators have not demonstrated a statistically significant relationship between cigarette smoking and mutation of the p53 gene but have reported a relatively low frequency of p53 mutations in cigarette smokers (27 , 28) . We identified p53 mutations in 58% of the smokers in the current study using two complementary sequencing methods. Previous work in our laboratory (17) has demonstrated that the use of direct sequencing and the p53 GeneChip assay will detect more mutations than the use of either technique alone.

The pattern of mutations in the p53 gene varies among cancer types and often provides clues to the pathogenesis of the tumor (10) . GCTA transversions were the most common mutation observed in the 95 smokers in this study and have also been commonly reported in other smoking-related cancers (esophagus, head and neck; Refs. 10 , 13 ). These mutations are the hallmark of mutagenesis involving certain types of polycyclic aromatic hydrocarbons, such as benzopyrene (10 , 12) . Mutations at CpG dinucleotides also occurred commonly in our series (32%) and have been reported in from 9 to 35% of non-small cell lung cancer patients (10 , 25) . Mutations at CpG dinucleotides are generally presumed to be secondary to the endogenous deamination of methylated cytosine, especially in colon cancer, in which 55% of mutations occur at CpG sites (10 , 30) . However, preferential binding of several carcinogens, including benzo(a)pyrene diol epoxide, has recently been demonstrated at methylated CpG sites corresponding to mutational hotspots in the p53 gene (30) . Benzo(a)pyrene diol epoxide-induced DNA damage at these CpG sites is poorly repaired and likely explains the high incidence of mutations at these sites in non-small cell lung cancer (31) .

Non-small cell lung cancer occurs infrequently in nonsmokers and has distinct clinical, pathological, and genetic features from cancer in patients with a history of cigarette smoking. One limitation to this study is the low number of nonsmokers with non-small cell lung cancer available for analysis. Adenocarcinoma is more common in nonsmokers, and, in our series, 90% of the nonsmokers had adenocarcinoma (10 , 32) . p53 mutations in non-small cell lung cancer are also more common in large-cell and squamous cancers than in adenocarcinoma. However, the frequency of p53 mutations in smokers with adenocarcinoma was still significantly higher than in the nonsmokers with adenocarcinoma (46 versus 0%). In the current series, too few mutations occurred in the nonsmokers to analyze the p53 mutational spectrum in this group. However, other series have reported an increased frequency of GCAT transitions and deletions in nonsmokers (27) . An increased incidence of K-ras mutations and chromosomal loss at the FHIT gene locus has also been associated with cigarette smoking (27 , 33) .

Loss of p53 tumor suppressor gene function allows the evolution of a clonal population of cells with a selective growth advantage that may result in cancer progression. Aberrant p53 expression has been documented in preneoplastic bronchial lesions and may be an important step in the progression of non-small cell lung cancer (34) . Moreover, p53 mutations may be associated with more aggressive behavior and shorter survival in non-small cell lung cancer (35) . Previous epidemiological data have strongly linked lung cancer with cigarette smoking and to a lesser degree heavy alcohol consumption. The present study did not examine the effect of cigarette smoking or alcohol consumption on the overall risk of developing lung cancer. However, our results demonstrate that alcohol consumption and cigarette smoking together increase the frequency of p53 gene mutations in patients with non-small cell lung cancer more than that observed with cigarette smoking alone. These data suggest that, although not necessarily mutagenic by itself, alcohol may potentiate the effects of other known carcinogens, thereby influencing the development and behavior of lung cancer.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported in part by the Lung Cancer Specialized Programs of Research Excellence (CA-58184-03).

² To whom requests for reprints should be addressed, at Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205-2196. Phone: (410) 502-5153; Fax: (410) 614-1411; E-mail: dsidrans{at}welchlink.welch.jhu.edu

Received 12/28/99. Accepted 5/ 2/00.

	REFERENCES

Top ABSTRACT Introduction Patients and Methods Results Discussion REFERENCES

 

1. Landis S., Murray T., Bolden S., Wingo P. Cancer Statistics, 1998. CA Cancer J. Clin., 48: 6-29, 1998.[Abstract]
2. Carbone D. Smoking and cancer. Am. J. Med., 93: 13-17, 1992.[Medline]
3. Shopland D. R., Eyre H. J., Pechacek T. F. Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States?. J. Natl. Cancer Inst., 83: 1142-1148, 1991.[Abstract/Free Full Text]
4. Carpenter C., Morgenstern H., London S. Alcoholic beverage consumption and lung cancer risk among residents of Los Angeles County. J. Nutr., 128: 694-700, 1998.[Abstract/Free Full Text]
5. Spitz M. R., Shi H., Yang F., Hudmon K. S., Jiang H., Chamberlain R. M., Amos C. I., Wan Y., Cinciripini P., Hong W. K., Wu X. Case-control study of D2 dopamine receptor gene and smoking status in lung cancer patients. J. Natl. Cancer Inst., 90: 358-363, 1998.[Abstract/Free Full Text]
6. Omenn G. S., Goodman G. E., Thornquist M. D., Balmes J., Cullen M. R., Glass A., Keogh J. P., Meyskens F. L., Jr., Valanis B., Williams J. H., Jr., Barnhart S., Cherniack M. G., Brodkin C. A., Hammar S. Risk factors for lung cancer and for intervention effects in CARET, the ß-Carotene and Retinol Efficacy Trial. J. Natl. Cancer Inst., 88: 1550-1559, 1996.[Abstract/Free Full Text]
7. De Stefani E., Correa P., Fierro L., Fontham E. T., Chen V., Zavala D. The effect of alcohol on the risk of lung cancer in Uruguay. Cancer Epidemiol. Biomark. Prev., 2: 21-26, 1993.[Abstract]
8. Dosemeci M., Gokmen I., Unsal M., Hayes R. B., Blair A. Tobacco, alcohol use, and risks of laryngeal and lung cancer by subsite and histologic type in Turkey. Cancer Causes Control, 8: 729-737, 1997.[Medline]
9. Vogelstein B., Kinzler K. W. Carcinogens leave fingerprints. Nature (Lond.), 355: 209-210, 1992.[Medline]
10. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.[Free Full Text]
11. Puisieux A., Lim S., Groopman J., Ozturk M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res., 51: 6185-6189, 1991.[Abstract/Free Full Text]
12. Denissenko M. F., Pao A., Tang M., Pfeifer G. P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science (Washington DC), 274: 430-432, 1996.[Abstract/Free Full Text]
13. Brennan J. A., Boyle J. O., Koch W. M., Goodman S. N., Hruban H. R., Eby Y. J., Couch M. J., Forastiere A. A., Sidransky D. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 332: 712-717, 1995.[Abstract/Free Full Text]
14. Field J. K., Spandidos D. A., Stell P. M. Overexpression of p53 gene in head-and-neck cancer, linked with heavy smoking and drinking. Lancet, 339: 502-503, 1992.
15. Mountain C. F. Revisions in the International System for Staging Lung Cancer. Chest, 111: 1710-1717, 1997.[Abstract/Free Full Text]
16. Sidransky D., Von Eschenbach A., Tsai Y. C. Identification of p53 mutations in bladder cancers and urine samples. Science (Washington DC), 252: 706-709, 1991.[Abstract/Free Full Text]
17. Ahrendt S. A., Halachmi S., Chow J. T., Wu L., Halachmi N., Yang S. C., Wehage S., Jen J., Sidransky D. Rapid p53 sequence analysis using an oligonucleotide probe array in primary lung cancer. Proc. Natl. Acad. Sci. USA, 96: 7382-7387, 1999.[Abstract/Free Full Text]
18. Anderson L. M., Chabra S. K., Nerurkar P. V., Souliotis L. V., Kyrtopoulos S. A. Alcohol-related cancer risk: a toxicokinetic hypothesis. Alcohol, 12: 97-104, 1995.[Medline]
19. Grafstrom R. C., Dypbukt J. M., Sundqvist K., Atzori L., Nielsen I., Curren R. D., Harris C. C. Pathobiological effects of acetaldehyde in cultured human epithelial cells and fibroblasts. Carcinogenesis (Lond.), 15: 985-990, 1994.[Abstract/Free Full Text]
20. Kondo K., Tsuzuki H., Sasa M., Sumitomo M., Uyama T., Monden Y. A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J. Surg. Oncol., 61: 20-26, 1996.[Medline]
21. Westra W. H., Offerhaus J. A., Goodman S. N., Slebos R. J. C., Polak M., Baas I. O., Rodenhuis S., Hruban R. H. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am. J. Surg. Pathol., 17: 213-220, 1993.[Medline]
22. Bongiorno P. F., Whyte R. I., Lesser E. J., Moore J. H., Orringer M. B., Beer D. G. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. J. Thorac. Cardiovasc. Surg., 107: 590-595, 1994.[Abstract/Free Full Text]
23. Liloglou T., Ross H., Prime W., Donnelly R. J., Spandidos D. A., Gosney J. R., Field J. K. p53 gene aberrations in non-small cell lung carcinomas from a smoking population. Br. J. Cancer, 75: 1119-1124, 1997.[Medline]
24. Suzuki H., Takahashi T., Kuroishi T., Suyama M., Ariyoshi Y., Takahashi T., Ueda R. Mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res., 52: 734-736, 1992.[Abstract/Free Full Text]
25. Husgafvel-Pursiainen K., Kannio A. Cigarette smoking and p53 mutations in lung cancer and bladder cancer. Eniviron. Health Perspect., 104(Suppl.3): 553-556, 1996.
26. Wang X., Christiani D. C., Wiencke J. K., Fischbein M., Xu X., Cheng T. J., Mark E., Wain J. C., Kelsey K. T. Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epidemiol. Biomark. Prev., 4: 543-548, 1995.[Abstract]
27. Marchetti A., Pellegrini S., Sozzi G., Bertacca G., Gaeta P., Buttitta F., Carnicelli V., Griseri P., Chella A., Angeletti C. A., Pierotti M., Bevilacqua G. Analysis of lung tumors of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus. Br. J. Cancer, 78: 73-78, 1998.[Medline]
28. Ryberg D., Kure E., Lystad S., Skaug V., Stangeland L., Mercy I., Borresen A. L., Haugen A. p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res., 54: 1551-1555, 1994.[Abstract/Free Full Text]
29. Chiba I., Takahashi T., Nau M., D’Amico D., Curiel D. T., Mitsudomi T., Buchhagen D. L., Carbone D., Piantadosi S., Koga H., Reissman P. T., Slamon D. J., Holmes E. C., Minna J. D. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene, 5: 1603-1610, 1990.[Medline]
30. Chen J. X., Zheng Y., West M., Tang M. Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots. Cancer Res., 58: 2070-2075, 1998.[Abstract/Free Full Text]
31. Denissenko M. F., Pao A., Pfeifer G. P., Tang M. Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. Oncogene, 16: 1241-1247, 1998.[Medline]
32. Brownson R. C., Loy T. S., Ingram E., Myers J. L., Alavanja M. C., Sharp D. J., Chang J. C. Lung cancer in nonsmoking women: histology and survival patterns. Cancer (Phila.), 75: 29-33, 1995.[Medline]
33. Sozzi G., Sard L., De Gregorio L., Marchetti A., Musso K., Buttitta F., Tornielli S., Pellegrini S., Veronesi M. L., Manenti G., Incarbone M., Chella A., Angeletti C. A., Patorino U., Huebner K., Bevilacqua G., Pilotti S., Croce C. M., Pierotti M. A. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res., 57: 2121-2123, 1997.[Abstract/Free Full Text]
34. Rusch V., Klimstra D., Linkov I., Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia, and coexpression precedes squamous cell carcinoma development. Cancer Res., 55: 1365-1372, 1995.[Abstract/Free Full Text]
35. Mitsudomi T., Oyama T., Kusano T., Osaki T., Nakanishi R., Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J. Natl. Cancer Inst., 85: 2018-2023, 1993.[Abstract/Free Full Text]

This article has been cited by other articles:

				M. Woenckhaus, U. Grepmeier, B. Werner, C. Schulz, F. Rockmann, P. J. Wild, G. Rockelein, H. Blaszyk, M. Schuierer, F. Hofstaedter, et al. Microsatellite Analysis of Pleural Supernatants Could Increase Sensitivity of Pleural Fluid Cytology J. Mol. Diagn., October 1, 2005; 7(4): 517 - 524. [Abstract] [Full Text] [PDF]

				D. E. Paull, G. M. Updyke, M. A. Baumann, H. W. Chin, A. G. Little, and S. A. Adebonojo Alcohol Abuse Predicts Progression of Disease and Death in Patients with Lung Cancer Ann. Thorac. Surg., September 1, 2005; 80(3): 1033 - 1039. [Abstract] [Full Text] [PDF]

				Y. Hu, M. P. McDermott, and S. A. Ahrendt The p53 Codon 72 Proline Allele Is Associated with p53 Gene Mutations in Non-Small Cell Lung Cancer Clin. Cancer Res., April 1, 2005; 11(7): 2502 - 2509. [Abstract] [Full Text] [PDF]

				C.-K. Toh, E.-H. Wong, W.-T. Lim, S.-S. Leong, K.-W. Fong, J. Wee, and E.-H. Tan The Impact of Smoking Status on the Behavior and Survival Outcome of Patients With Advanced Non-small Cell Lung Cancer: A Retrospective Analysis Chest, December 1, 2004; 126(6): 1750 - 1756. [Abstract] [Full Text] [PDF]

				A Ruano-Ravina, A Figueiras, and J M Barros-Dios Type of wine and risk of lung cancer: a case-control study in Spain Thorax, November 1, 2004; 59(11): 981 - 985. [Abstract] [Full Text] [PDF]

				J. L. Freudenheim, M. Bonner, S. Krishnan, C. B. Ambrosone, S. Graham, S. E. McCann, K. B. Moysich, E. Bowman, T. Nemoto, and P. G. Shields Diet and alcohol consumption in relation to p53 mutations in breast tumors Carcinogenesis, June 1, 2004; 25(6): 931 - 939. [Abstract] [Full Text] [PDF]

				P. P. Medina, S. A. Ahrendt, M. Pollan, P. Fernandez, D. Sidransky, and M. Sanchez-Cespedes Screening of Homologous Recombination Gene Polymorphisms in Lung Cancer Patients Reveals an Association of the NBS1-185Gln Variant and p53 Gene Mutations Cancer Epidemiol. Biomarkers Prev., August 1, 2003; 12(8): 699 - 704. [Abstract] [Full Text] [PDF]

				S. A. Ahrendt, Y. Hu, M. Buta, M. P. McDermott, N. Benoit, S. C. Yang, L. Wu, and D. Sidransky p53 Mutations and Survival in Stage I Non-Small-Cell Lung Cancer: Results of a Prospective Study J Natl Cancer Inst, July 2, 2003; 95(13): 961 - 970. [Abstract] [Full Text] [PDF]

				L. Djousse, J. F. Dorgan, Y. Zhang, A. Schatzkin, M. Hood, R. B. D'Agostino, D. L. Copenhafer, B. E. Kreger, and R. C. Ellison Alcohol Consumption and Risk of Lung Cancer: The Framingham Study J Natl Cancer Inst, December 18, 2002; 94(24): 1877 - 1882. [Abstract] [Full Text] [PDF]

				M. Miyaki, T. Iijima, R. Ishii, Y. Kita, M. Koike, T. Kuroki, and T. Mori Increased Frequency of p53 Mutation in Sporadic Colorectal Cancer from Cigarette Smokers Jpn. J. Clin. Oncol., June 1, 2002; 32(6): 196 - 201. [Abstract] [Full Text] [PDF]

				R.-H. Wong, C.-L. Du, J.-D. Wang, C.-C. Chan, J.-C. J. Luo, and T.-J. Cheng XRCC1 and CYP2E1 Polymorphisms as Susceptibility Factors of Plasma Mutant p53 Protein and Anti-p53 Antibody Expression in Vinyl Chloride Monomer-exposed Polyvinyl Chloride Workers Cancer Epidemiol. Biomarkers Prev., May 1, 2002; 11(5): 475 - 482. [Abstract] [Full Text] [PDF]

				K. Conway, S. N. Edmiston, L. Cui, S. S. Drouin, J. Pang, M. He, C.-K. Tse, J. Geradts, L. Dressler, E. T. Liu, et al. Prevalence and Spectrum of p53 Mutations Associated with Smoking in Breast Cancer Cancer Res., April 1, 2002; 62(7): 1987 - 1995. [Abstract] [Full Text] [PDF]

				S. A. Ahrendt, S. C. Yang, L. Wu, C. M. Roig, P. Russell, W. H. Westra, J. Jen, M. V. Brock, R. F. Heitmiller, and D. Sidransky Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: Preliminary results of a prospective study J. Thorac. Cardiovasc. Surg., March 1, 2002; 123(3): 466 - 474. [Abstract] [Full Text] [PDF]

				P. Wolf, Y. C. Hu, K. Doffek, D. Sidransky, and S. A. Ahrendt O6-Methylguanine-DNA Methyltransferase Promoter Hypermethylation Shifts the p53 Mutational Spectrum in Non-Small Cell Lung Cancer Cancer Res., November 1, 2001; 61(22): 8113 - 8117. [Abstract] [Full Text] [PDF]

				F. Biramijamal, A. Allameh, P. Mirbod, H.-J. Groene, R. Koomagi, and M. Hollstein Unusual Profile and High Prevalence of p53 Mutations in Esophageal Squamous Cell Carcinomas from Northern Iran Cancer Res., April 1, 2001; 61(7): 3119 - 3123. [Abstract] [Full Text]

				P. Hainaut and G. P. Pfeifer Patterns of p53 G{->}T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke Carcinogenesis, March 1, 2001; 22(3): 367 - 374. [Abstract] [Full Text] [PDF]

				M. Sanchez-Cespedes, P. A. Decker, K. M. Doffek, M. Esteller, W. H. Westra, E. A. Alawi, J. G. Herman, M. J. Demeure, D. Sidransky, and S. A. Ahrendt Increased Loss of Chromosome 9p21 but not p16 Inactivation in Primary Non-Small Cell Lung Cancer from Smokers Cancer Res., March 1, 2001; 61(5): 2092 - 2096. [Abstract] [Full Text]

				M. Sanchez-Cespedes, S. A. Ahrendt, S. Piantadosi, R. Rosell, M. Monzo, L. Wu, W. H. Westra, S. C. Yang, J. Jen, and D. Sidransky Chromosomal Alterations in Lung Adenocarcinoma from Smokers and Nonsmokers Cancer Res., February 1, 2001; 61(4): 1309 - 1313. [Abstract] [Full Text]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ahrendt, S. A. Articles by Sidransky, D. Search for Related Content PubMed PubMed Citation Articles by Ahrendt, S. A. Articles by Sidransky, D.